Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
Twitter Feed
-
We are committed to serving the global immune thrombocytopenia (ITP) community. Colleagues around the world are joining in, sporting their best purple. #PlateletsDay #ITPAware https://t.co/xxKnjRC6ra
— UCB News (@ucb_news) 25.09.2020 -
This #pandemic is impacting some communities more than others. We asked ourselves what we could do to help and promptly set up the UCB Community Health Fund. You can find out about its mission and its first Call for Projects below. https://t.co/Nbkw2Vk8wt
— UCB News (@ucb_news) 24.09.2020 -
We are committed to supporting patients through their rare disease journeys. For rare diseases like immune thrombocytopenia (#ITP), each patient's experience and symptoms are unique. That's why we are elevating voices like Jaimie's. #ITPAware
— UCB News (@ucb_news) 24.09.2020
Instagram Feed
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
